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resumo 
 
 
A Doença de Alzheimer tem como uma das suas características principais, os 
depósitos do péptido tóxico Aβ, conhecidos como placas senis (PS). O péptido 
tóxico é produzido por complexas vias intracelulares e clivagens da Proteína 
Precursora Amiloide (PPA). Vários aspetos são importantes para o 
processamento da PPA. Entre eles, as proteínas que se ligam à PPA e formam 
diferentes complexes que são funcionalmente relevantes. Estudos recentes 
demonstraram que o estado de fosforilação da própria PPA é determinante 
para a formação desses complexos. Portanto, o estado de fosforilação da PPA 
determina o seu próprio destino, o rácio de produção de Aβ e a formação de 
placas senis. É também digno de nota que pacientes com mutação Swedish 
produzem cerca de 10 vezes mais Aβ. 
O objetivo desta tese é considerar os fatores acima mencionados que 
modulam a produção de Aβ numa perspetiva única. Ou seja, considerar como 
a fosforilação da PPA afeta a produção de Aβ, tendo em conta o próprio 
estado fosforilado da proteína e os complexos proteicos que dai são formados. 
De modo a responder a essas questões, várias ferramentas biológicas tem que 
ser disponibilizadas. Consequentemente, esta tese propõem-se a preparar 
mutações Swedish na PPA (para produzir 10 vezes mais Aβ), a partir de cDNA 
da PPA que expressa mutações que imitam a fosforilação da Thr668. Este 
objetivo foi conseguido e foi possível demonstrar que as referidas mutações 
produziram níveis consideravelmente altos do péptido tóxico. Estudos 
preliminares de imunocitoquímica permitiram avaliar a distribuição celular dos 
mutantes produzidos, bem como da PP1γ em células SH-SY5Y, mas mais 
estudos são necessários para avaliar a co-localização do complexo proteico 
trimérico entre os mutantes da PPA, PP1γ e Fe65. 
Assim sendo, estudos adicionais poderão contribuir para um melhor 
conhecimento da maneira como a produção de Aβ é influenciada por 
complexos proteicos regulados pela fosforilação da PPA. 
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abstract 
 
Alzheimer’s disease has as one of its characteristic hallmarks, deposits of a 
toxic peptide Aβ, known as senile plaques (SP). The toxic peptide is produced 
via complex intracellular pathways and cleavage of the Alzheimer’s Amyloid 
Precursor Protein (APP). Several aspects are key to APP processing. Among 
them, the proteins that bind to APP and form different complexes, which are 
functionally relevant. Recent studies have shown that the phosphorylation state 
of APP itself is determinant with respect to the protein complexes formed. Thus 
the protein’s phosphorylation state ultimately determines its own fate, the rate 
of Aβ production and the formation of SPs. It is also noteworthy the patients 
with Swedish mutation produced 10 times more Aβ. 
The aim of this thesis is to consider the above mentioned factors, which 
modulate Aβ production in a unified perspective. That is, to consider how 
protein phosphorylation affects Aβ production, bearing in mind the 
phosphorylated state of the protein itself and the complexes that are formed. In 
order to address these questions, several biological tools have to be available. 
Hence this thesis set out to prepare the APP Swedish mutations (to produce 10 
times more Aβ) on a cDNA which also expressed phosphorylation site 
mutations on APP Thr668. This was achieved and it was possible to 
demonstrate that the resulting mutations did in fact produce considerably 
higher levels of the toxic peptide. Preliminary immunocytochemistry studies 
allowed for assessment of cellular distribution of the mutants and PP1γ in SH-
SY5Y cells, and more studies are needed to assess the co-localization of the 
trimeric protein complex between the APP mutants. PP1γ and Fe65. 
Therefore additional studies could contribute to a better understanding of the 
way that Aβ production is influenced by protein complexes regulated by APP 
phosphorylation.  
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1. Introduction 
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1.1. Alzheimer’s disease (AD) 
 
As the life expectancy of people around the world increases, it is projected that the 
number of elderly individuals developing dementia will also increase to 106 million 
worldwide by the year of 2050 (1,2). Dementia is characterized by a progressive decline in 
intellectual functions, such as memory, retention of information, attention and problem 
solving. This decline is only significant when it surpasses the normal changes related with 
the increase of age in normal individuals (3,4). Between all possible causes to develop 
dementia there are numerous neurologic diseases, such as frontotemporal dementia, 
dementia with Lewy bodies, vascular dementia, Alzheimer’s disease, among others (2–5). 
Alzheimer’s disease (AD) is the most common cause of dementia in elderly people, 
constituting about 70% of all cases of dementia (5,6). In 2011, 25 million people were 
affected by AD worldwide (5). The first known case of AD occurred in 1907, when Alois 
Alzheimer studied a patient with symptoms like hallucinations and memory loss; the post-
mortem examination revealed an evidently atrophic brain, with the presence of fibrils and 
deposits of a pathological material (5). 
Since then, AD is clinically characterized by a progressive loss of memory, unusual 
behavior, dysfunction of personality and by a variability of other clinical findings 
associated with the affected brain regions, such as malfunctions in speech, vision and 
judgment, as well as mood changes (3,5,7). At a cerebral level, the brain of AD patients 
suffers a characteristic atrophy and mass loss, leading to an overall shrinkage, affecting 
specific areas like the cerebral cortex and hippocampus (4,8).  
It is a progressive neurodegenerative disease, which starts as short-term memory 
loss episodes and with a slight decrease in the ability of performing simple and routine 
tasks , ultimately leading to a complete inability to live, culminating with death of the 
patients, due to other conditions, typically pneumonia, between 3 to 9 years after diagnosis 
(5,9). There is still no cure available at the moment (10). 
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1.1.1. Histopathological Hallmarks 
On a cellular and molecular level, aside from loss of synapses, dendrites and 
neurons, there are two main histopathological hallmarks that define AD: intracellular 
neurofibrillary tangles (NFTs) and extracellular senile plaques (SP) (Figure 1) (5,8). These 
neuropathological findings present in the cortex and hippocampus of AD patients at higher 
levels than in the same age matched controls (7,11).  
 
 
NFTs consists of intracellular aggregates of hyperphosphorylated microtubule-
associated protein tau (7,12). Tau protein is regulated by its phosphorylated state. In 
normal conditions, this protein is not hyperphosphorylated and stabilizes neurons 
microtubules, especially in axons. When hyperphosphorylated, tau protein destabilizes 
microtubules by detaching from them and then accumulates to form insoluble tau 
aggregates into paired helical filaments (PHF). This leads to formation of NFTs in neurons 
of AD brains (7,12).  
SP, on the other hand, are extracellular proteinaceous accumulations of a product of 
APP processing, amyloid beta (Aβ) peptides (12,13). This 4kDa peptide in its β-sheet 
Figure 1 – Schematic representation of an AD brain and a normal brain.  
The AD brain is represented on the right side and the normal brain on the left side. The neuronal structure 
is indicated as well as the site of NTF and SP deposits. A clear shrinkage is seen on AD brain section 
(taken from https://stanfordhealthcare.org/medical-conditions/brain-and-nerves/alzheimers-disease.html). 
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conformation is the main component of these large, dark and circular plaques (12). Aβ is 
found in healthy individuals as a normal physiological metabolite in an natively unfolded 
form (14–16). Not so much is known about its physiological function, only that it induces 
Long term potentiation (LTP) in hippocampus, and that the inhibition of its production 
leads to cell death. But as people age, changes occur in Aβ formation and metabolism, 
leading to the aggregation and deposition of Aβ in the form of plaques (SP) (15,17). This 
happens several decades before any clinical symptoms appear, and the observation of both 
SP and NTFs can only be confirmed post mortem (14,18). However, recent advances in 
diagnostic imaging are permitting earlier detection in the brains of AD patients, this is 
discussed below.  
 
1.1.2. Epidemiology and Genetics  
 
Over 25 million people in the world are affected by AD. Of all the cases, only 1 to 
5% are due to mutations in specific genes (19). Normally, mutations in the amyloid 
precursor protein (APP), presinilin 1 (PSEN1) and presinilin 2 (PSEN2) genes, are all 
autosomal dominant, leading to premature onset of familial AD (FAD), that develop 
symptoms of AD before the age of 65 (19–21). The remaining AD cases represent sporadic 
forms of AD, in which the causes are not associated directly with any known mutation, are 
way more complex and implicate dysregulation of repair mechanisms, of cell metabolism 
and immune and inflammatory processes (13,21). However, the pathology of FAD and 
sporadic form of AD is very similar, comprising the same histopathological findings 
(22,23).  
There are a lot of risk factors associated with AD. The main risk factor of AD, and 
the most often ignored, is the increase of age. As AD can occur around the age of 50, it 
suggests that the disease develops by some unknown age-related process. The risk is higher 
for individuals with age of 65 or older, and even higher above 85 years, when the risk 
increases almost 50 percent (24).  
Other risk factors are known, including gender (females have a greater risk of 
developing AD), family history of dementia (patients with family members with AD are 
more likely to develop the disease), vascular changes, low level of education and genetic 
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and environmental factors (5,13,24,25). It is still unclear if smoking has some association 
with the development of AD (25).  
In contrast, regular physical exercise and a cognitively stimulating environment are 
known to be neuroprotective, leading to enhanced brain activity and likewise neuronal 
survival and resistance (25,26).  
 
1.1.2.1. Genetic risk factors 
 
Aside from the previously referred mutations that will develop FAD, there are other 
genetic factors that will increase the risk of developing AD. The major genetic risk factor 
is apolipoprotein E (APOE) ε4 allele (27). 
 ApoE proteins (35-kDa, 299 amino acid) are members of the plasma lipid-binding 
protein family, present in higher concentrations in the liver and brain. These proteins are 
presented in High Density Lipoprotein (HDL)-like lipoproteins and are involved in 
transport and delivery of cholesterol and triglycerides between cells, regulating lipid 
homeostasis (18,28–30). It is produced mostly by astrocytes and is also implicated in 
removal of Aβ fragments by action of enzymes like neprilysin or by receptor-mediated 
uptake (18,31–33).  
The APOE gene sequence is prone to variation, resulting in 3 types of alleles (ε2, 
ε3 and ε4). The alleles differ from one another in their amino acid composition at positions 
112 and 158 (3,6,28). These simple amino acid differences change the structure of ApoE in 
a way that its ability to bind to lipids, receptors and Aβ is different between the existing 
isoforms (6,28,29). The ε4 allele of ApoE is known to be a major risk factor to develop 
AD, while the ε2 and ε3 allele are protective and the most common forms, respectively 
(28,34,35). Patients with two ε4 alleles (Homozygosity) have between 50% to 90% chance 
of developing AD until the age of 85, while the presence of only one ε4 allele 
(Heterozygosity) increases the chance to 45% (18,28).  
ApoE is involved in Aβ metabolism and is a constituent of AD’s SP, but its role in 
the development of the disease is still unknown (18,28). ApoE4’s role in AD seems to be a 
combination of a gain in toxic function and loss of neuroprotective functions (28,29). The 
presence of ApoE4 highly influences and accelerates the formation of Aβ and its 
deposition into SP, this contrasts with the presence of ApoE3 (18,28). It appears that 
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ApoE4 is responsible for the initiation of SP formation in the brain (28). It is speculated 
that ApoE is a chaperone for Aβ fragments, regulating its conversion from an α-helix to a 
β-sheet conformation (6,18,30). The clearance of Aβ is also affected by the presence of 
ApoE4, leading to less efficient removal of Aβ and promoting Aβ aggregation and 
formation of senile plaques. ApoE4 is not so efficient in the removal of Aβ peptides when 
compared to ApoE3, which is consistent with ApoE4 having a lower affinity for Aβ 
peptides than ApoE3. Besides, elimination of Aβ peptides by specialized enzymes is 
confirmed to be more efficient with ApoE3 than with ApoE4, and reduced expression of 
those enzymes is observed in the presence of ApoE4 (6,18,28).  Despite its important but 
unknown role in AD, the knockout of the APOE gene does not reveal improved 
neurological function, in part due to other types of lipoproteins acting in substitution of 
ApoE (6,13).  
ApoE4 is not only related to Aβ metabolism. It also seems to have a role in 
inflammatory processes, initiating cascades that will culminate in neurovascular 
dysfunctions. Among these dysfunctions, the breakdown of the BBB and posterior leakage 
of blood toxins into the brain seem to be implied in the development of AD (28).  
ApoE4 is the best characterized genetic risk factor, but mutations on other genes with a 
role in Aβ production and clearance also increase the risk of developing AD. This is the 
case for mutations in the SORL1, PICALM, CLU, CR1 or BIN1 genes (Table 1) (24,27). 
 
GENE GENETIC FORM ONSET 
AMYLOID PRECURSOR PROTEIN (APP) Autosomal Dominant Early 
PRESENILIN 1 (PSEN1) Autosomal Dominant Early 
PRESINILIN 2 (PSEN2) Autosomal Dominant Early 
APOLIPOPROTEIN E4 (APOE4) Familial and Sporadic Late 
SORTILIN-RELATED RECEPTOR L (DLR 
CLASS) A REPEATS-CONTAINING (SORL1) 
Familial and Sporadic Late 
CLUSTERIN (CLU) Sporadic Late 
PHOSPHATIDYLINOSITOL BINDING 
CLATHRIN ASSEMBLY PROTEIN 
(PICALM) 
Sporadic Late 
COMPLEMENT COMPONENT (3B/4B) 
RECEPTOR 1 (CR1) 
Sporadic Late 
BRIDGING INTEGRATOR 1 (BIN1) Sporadic Late 
Table 1 – Genetic factors associated with Alzheimer’s Disease  
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1.1.3. Diagnosis  
 
Nowadays, the average span of time from diagnosis of AD to death is 4 to 8 years, 
despite the long time that the disease can take to run its course (around 20 years) (36). This 
means that diagnosis of AD is still done too late in the course of the disease (Figure 2). 
Diagnosing AD is difficult and most of the time unspecific. AD is still diagnosed by ruling 
out other neurologic disorders with similar symptoms, and the only way to definitely 
diagnosis the disease is by carrying out histological observation of the brain during autopsy 
(5,36).  
 
 
However, new tools were developed that are now helping in the early diagnosis of 
this disease. Aside from an improvement in obtaining information by patient’s and 
family’s medical history, neurological examination and laboratory exams, neuroimaging 
techniques are improving drastically the diagnosis of AD. Techniques like Positron 
Emission Tomography (PET), Magnetic Resonance Imaging (MRI) or Computerized 
Tomography (CT) are now known as neuroimaging biomarkers in AD, providing structural 
and functional details of the patient’s brain (5,37,38). Alternatively, AD biomarkers in 
Cerebrospinal Fluid [CSF] are presently being put into practice. The early detection of AD 
Figure 2 – Time course of AD’s histopathological changes in relation to its clinical stages. 
One of the first events that occur on normal people that will develop AD is aggregation of Aβ peptides in 
the form of SP. Over the years, SP continue to be formed, and tau accumulation begins to increase, 
leading to a moderate decrease of neuronal functions. As accumulation of Aβ and tau continues to 
increase, individuals start to lose its neuronal functions. AD’s diagnosis occurs when Aβ accumulation is 
at its peak and neuronal integrity cannot be reversible (very mild AD) (taken from (30)). 
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patients can be carried out by testing the CSF for Aβ42 and phosphorylated and total tau 
protein (Table 2), but more biomarkers need to be identified and approved to allow for a 
better early detection, and to manage the progression of the disease, as well to generate 
new and efficient treatments (36,39). Currently, most AD biomarkers only indicate the risk 
of an individual to develop the disease, not the presence of the disease itself (27,36). 
 
BIOMARKER PLASMA CSF 
AΒ1-42 High Low 
T-TAU Slight high High 
P-TAU Slight high High 
 
Due to its prolonged development, increasing prevalence, difficult and unspecific 
diagnosis and high costs to the health systems and  families, AD is now considered a major 
worldwide public health issue (14,18). Regrettably, to date there is no cure or way to 
prevent this disease, and the causes are yet to be fully understood (3,14). Current 
treatments focus in delaying of disease progression, management of symptoms and 
neuroprotective approaches in order to maintain a good mental function (40). In the future, 
AD’s therapies will mostly rely on anti-amyloid therapies, by reducing Aβ production or 
increasing Aβ clearance.  
 
1.2. Amyloid Precursor Protein (APP) 
 
Human APP is a type I transmembrane protein, in the same family as APP-like 
protein 1 (APLP-1) and APP-like protein 2 (APLP-2). It has a large extracellular amino-
terminal portion, and a short intracellular carboxyl-terminal portion (41–43). Human APP 
is encoded by the APP gene, located on chromosome 21. Due to alternative splicing of 
exons 7 and 8, APP exhibits three major isoforms that differ in the number of amino acids: 
APP695, APP751 and APP770 (Figure 3) (43–45). These APP isoforms are expressed in 
different types of tissues: APP695 is mostly expressed in neurons, while APP751 and 
Table 2 – Fluid biomarkers of AD 
Aβ1-42, total tau (t-Tau) and hyperphosphorylated tau (p-Tau) levels in plasma and CSF. 
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APP770 are expressed in all kinds of tissues (23,43). Whereas APP751 and APP770 have a 
Kunitz Protease Inhibitor (KPI) domain in their extracellular region, APP695 lacks that 
same domain (43). Among a lot of domains located in the N-terminal portion of APP, the 
most well-known and studied is the Aβ domain (41,46).  
 
The Aβ domain has part of its peptides embedded within the membrane (26). When 
cleaved by specific secretases, the Aβ fragment is released in an unfolded state (14). This 
fragment can have different lengths (37 to 43 amino acids) depending on the site of 
cleavage by γ-secretases (Figure 4) (42). The most abundant Aβ fragment is Abeta40 (40 
amino acids), but the most toxic Aβ fragment is Abeta42 (42 amino acids), probably due to 
its capacity to form oligomers and protofibrils faster than the other peptide species 
(9,14,42). The role of Aβ peptides in the development of AD has not been totally 
elucidated, and current theories point Aβ peptides oligomerization , contributing to rapid 
calcium leakage or to mitochondrial dysfunction, while several neuronal receptors have 
been discovered to bind Aβ peptides (14,33).  
Figure 3 – Schematic representation of major APP isoforms in mammalian tissues. 
Numbers and vertical lines show the corresponding exons approximately at scale. APP695, comprising 
695 amino acids, is the most abundant APP isoform. APP695 do not express exons 7 and 8, unlike 
APP751 and APP770. APP751 differ from APP770 due to alternatively splicing of exons 7 and 8, as 
shown. Aβ region is represented as a solid black region between exons 16 and 17 (taken from (45)). 
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1.2.1. APP synthesis and transport 
 
Full-length APP (110kDa) is synthesized in the Endoplasmic Reticulum (ER). 
Following its synthesis, it is transported to and through the Golgi apparatus until it reaches 
the trans-Golgi-network (TGN), where in neurons, it is found at its highest concentration 
(Figure 5) (42,43). From here, a small fraction (10%) of APP is directed to the surface of 
the plasma membrane, being transported in secretory vesicles derived from TGN by the 
anterograde transport system (11,42,43). Having reached the plasma membrane, APP can 
either be cleaved by cell-membrane secretases or be internalized within minutes of arrival 
via the endosomal systems (42,43). Endocytosis of APP is possible due to the “YENPTY” 
motif present near its C-Terminus. This motif is involved in clathrin-coated vesicle 
internalization (23). APP is transported to endosomes (Figure 5), where it can be recycled 
to the plasma membrane or be delivered to lysosomes to degradation (11,42). 
Figure 4 – γ -Secretase cleavage sites. 
APP processing by gamma-secretase is not limited to only one site. The final cleavage by gamma-
secretase is not precise and can take place at least between amino acids 37 and 43 of the A Beta domain, 
producing A Beta peptides with different lengths (adapted from (42)). 
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APP is concentrated in lipid rafts (LR) (Figure 6). LR are small membrane 
microdomains (~50nm) enriched with cholesterol, sphingolipids, proteins, and have a 
small amount of gangliosides (47–49). They are described as highly dynamic domains, 
with a nanoscale dimension, present abundantly in the plasma membrane (47,48). About 
30 to 70% of the plasma membrane surface is constituted of LR, despise their small size 
(50,51). They function as membrane platforms that incorporate specific proteins of the 
membrane bilayer needed to initiate cellular functions (47,48). LR seem to be involved in 
apoptosis, cell polarization, adhesion and movement, regulation of endo and exocytosis, 
vesicular trafficking, membrane and protein sorting, cell migration and initiation of cell 
signalling pathways (47,48,51–53). 
Several types of protein reside in the inner or outer leaflet of the LR (Figure 6). 
Proteins linked covalently to glycosylphosphatidylinositol (GPI) are a major component of 
the outer leaflet, while the inner leaflet of LR is filled with singly or multiply acylated 
Figure 5 – Schematic illustration of intracellular trafficking of APP 
1) Nascent APP matures through the constitutive secretory pathway until it reaches the plasma 
membrane; 2) On the plasma membrane, APP is rapidly internalized and 3) is trafficked through 
endocytic and recycling compartments back to the plasma membrane or to lysosomes, to be degraded 
(taken from (11)). 
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proteins (e.g. G-proteins. tyrosine kinases, protein phosphatases) (35,52,54). Numerous 
protein receptors are also found in LR, such as PDGF, EGF or cytokine receptors, as well 
as protein channels (44,54,55). Transmembrane proteins, like APP, are highly expressed in 
LR  due to specific sequences in their extracellular, intracellular or transmembrane domain 
(50,56). 
 
 
 
1.2.2. APP proteolytic processing 
 
APP is a highly expressed protein in neurons and is rapidly metabolized (23). Two 
distinct pathways can process APP: the amyloidogenic and the non-amyloidogenic 
pathway; both occur in cellular membranes, most specifically in lipid rafts. Lipid rafts, as 
said before, are membrane microdomains rich in cholesterol and sphingolipids. This 
special composition makes these domains prone to attract some types of proteins in 
preference to others, thus favoring some cellular processes. Regarding AD, lipid rafts are a 
subcellular site where most of the APP processing players coexist. To be more precise, 
APP, β-secretases and γ-secretases have all been found in lipid rafts (31).  
Figure 6 – Schematic representation of a membrane lipid raft. 
Lipid rafts are small membrane microdomains enriched in gangliosides, cholesterol and sphingolipids 
(the last one is not represented on the figure). Several types of proteins are associated with lipid rafts, like 
GPI-anchored proteins and transmembrane proteins (taken from (48)). 
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The two, above mentioned, processing pathways share some common players, 
these compete with each other in certain subcellular compartments and contribute to the 
relatively short half-life of APP (42,57).  
The amyloidogenic pathway leads to formation of Aβ fragments (Figure 7). APP is 
first cleaved by the action of a β-secretase. This secretase releases a large portion of the 
ectodomain of APP. The soluble fragment released is called sAPPβ (41,58). After β-
cleavage, the remaining fragment of APP, a 99 amino-acid Carboxyl Terminal Fragment 
(CTF),  called C99 (12 kDa), is still attached to the membrane (43,57–59). This C99 will 
be cleaved by a γ-secretase, releasing 2 more fragments: Aβ and the APP Intracellular 
Domain (AICD) (43,57,58).  
The non-amyloidogenic pathway does not produce Aβ fragments (Figure 7). 
Instead of being cleaved by a β-secretase, APP is first cleaved by α-secretase (14,58). α-
secretase cleaves within the Aβ region (between Lys16 and Lys17), preventing the 
formation of Aβ fragments. The soluble fragment released will also be different, in this 
case it is denominated sAPPα (14,44,58). sAPPα differs from sAPPβ because the first 
contains the Aβ 1-16 region at its C-Terminus, due to the  α-secretase cleavage (43).  The 
fragment that remains in the membrane is known as C83 (10 kDa), due to its 83 amino-
acid constitution (57,58). C83 then suffers the same fate as C99: cleavage by a γ-secretase, 
releasing p3 (3 kDa) and AICD fragments (57,58). The p3 fragment seems not to be 
pathological (42). 
Additionally, APP can be processed at its C-Terminus by the action of caspases like 
caspase-3, -6 and -8, resulting in a C31 peptide that seems to be an inducer of apoptosis.  
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Although the formation of toxic Aβ fragments its said to be one of the leading 
causes of AD, α and β- secretase compete with each other for APP, and in 90% of the cases 
APP is cleaved by α-secretase (non-amyloidogenic pathway) (58,59). 
Endocytosis also seems to have an important role in Aβ generation (44). Despite β-
secretases and APP being confined to lipid rafts, this by itself is not enough to induce β-
cleavage. Studies that inhibit cell endocytosis show no Aβ generation, but instead p3 
production is enhanced, due to α-secretase occurring mostly at the cell surface (44,49). 
Endocytosis seems to be needed to further proceed in Aβ generation, supporting the theory 
that β-cleavage occurs in the last steps of the secretory pathway, mostly at the cell surface 
and during endocytosis, as described before (49). 
 
1.2.2.1. β-secretase 
  
In the brain, studies have shown that the major β-secretase is the β-site APP 
cleaving enzyme (BACE1) (41,43). BACE1 is characterized as a type I transmembrane 
Figure 7 – Schematic diagram of APP proteolytic processing. 
Three different APP processing pathways are represented. The first is the non-amyloidogenic pathway 
(1), in which alpha-secretase enables the secretion of sAPP alpha into the extracellular space, while the 
action of the gamma-secretase complex will release the p83 (or p3) and AICD fragments The 
amyloidogenic pathway (2) leads to the formation of A Beta instead of p3, due to the action of a Beta-
secretase. APP can also be cleaved by the action of caspases (3), forming the C31 fragment. The different 
fragments are not drawn in proportion (adapted from (43)). 
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metalloproteinase, with its active site in the extracellular portion and found in high levels 
in neurons but at low levels in glia cells (23,42,58). BACE1 is generated from a large 
precursor (pro-BACE1) in the ER. This precursor is first modified by reactions of 
phosphorylation, palmitoylation, sulfation and glycosylation and finally is cleaved by a 
furin-like endoprotease in the Golgi, generating the mature BACE1 (70 kDa) (43,58,60). 
Both pro-BACE1 and BACE1 have protease activity and can mediate the first step in Aβ 
generation (58,60,61). 
It is now known that BACE1 is the major β-secretase involved in APP processing 
and that it is essential to generate Aβ fragments (43,58,61). Due to its optimal activity in 
acidic environments (pH 4.5), BACE1 is mainly present in endosomes and early and late 
Golgi endosomes, snd co-localizes with APP-rich subcellular compartments. However, 
BACE1 can also be found on cell surface (23,43,58).  
BACE was discovered to be present in lipid rafts; three of its cysteine residues are 
palmitoylated, which is a characteristic feature of lipid-raft associated proteins (59). 
Consistent with APP being cleaved most of the time by α-secretases, and the fact 
that APP does not present the optimal cleavage site for BACE, others substrates of BACE1 
have been discovered, such as APLP1, APLP2, sodium-channel β-subunit, neuregulin-1, 
low-density lipoprotein receptor (LDLR)-related protein (LRP), among others (15,58,60). 
This cogitates a normal function of BACE1 in the myelination process (42,60). 
Another β-secretase that has been found, is BACE2. Although it has 60 to 70% of 
amino acid similarity with BACE1, this secretase is found in lower amounts in neurons 
when compared to BACE1 and it acts differently: it cleaves better near the α-secretase 
region than at the β-secretase region, eradicating Aβ production (43,58,60).  
  
1.2.2.2. Gamma-secretase 
 
γ-secretase is described as a multimeric protein complex with high molecular 
weight, that has in its composition four components: presinilin (PS1 or PS2), presinilin 
enhancer-2 (PEN-2), Nicastrin and anterior pharynx-defective-1 (APH-1) (23,43). All 
these four subunits are essential for enzymatic activity of the γ-secretase complex (Figure 
8) (23,43).  
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Presinilins are multi-transmembrane proteins without a fixed number of 
transmembrane domains. There are two presinilins in mammals, PS1 and PS2. After being 
expressed, they suffer endoproteolytic cleavage. Then, a functional presinilin heterodimer 
is formed with the amino-terminal fragment (NTF) and the CTF produced by cleavage 
(42,43).  Due to its two highly conserved aspartate residues, and the fact that the presinilin 
heterodimers are connected to γ-secretase inhibitors, presinilins are known to be the 
catalytic subunits of γ-secretase (43). Nicastrin, a type I transmembrane protein, is the 
recruiting protein of the γ-secretase complex that will bind to APP and other substrates, 
recruiting them to the multimeric complex (43). The main function of APH-1 is to interact 
with Nicastrin and stabilize it, while PEN-2 has a regulatory function in the γ-secretase 
complex, initiating the cleavage of PS1 or PS2 to form the PS heterodimer (23,42,43).  
 
 
Apart from these four components, other factors have been proposed to be part of 
the γ-secretase complex. However, these factors seem to play a support role instead of 
being essential for γ-secretase activity (43). 
Figure 8 – Schematic diagram of the gamma-secretase complex. 
The gamma-secretase is a multi-protein complex responsible for the intramembrane proteolysis of several 
proteins. It is constituted by a catalytic subunit (PSEN1/PSEN2), a recruiting subunit (Nicastrin), a 
scaffold subunit (APH1) and a subunit responsible to the endoproteolysis of PSEN1/PSEN2 (PEN2) 
(adapted from (85)). 
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The γ-secretase multimeric complex has a specific subcellular localization: is 
mostly located in the plasma membrane, ER, endocytic compartments and Golgi apparatus 
(especially in TGN) (42,43). The γ-secretase complex is also found in lipid rafts, due to 
posttranslational palmitoylation (14,59). The process of palmitoylation seems to be crucial 
in the stabilization of Nicastrin and Aph-1 (44). 
γ-secretase has some substrates beyond APP, such as Notch, cadherin or CD44 
(43). Notch is mostly cleaved at the plasma membrane, while APP generally suffers its 
final cleavage at endocytic vesicles and at the TGN. This demonstrates that cleavage of γ-
secretase substrates is reliant on the specific subcellular compartments that they share 
(42,43).  
In the final step of APP processing, the protein site  where γ-secretase will act is 
not precise, it appears that the Aβ cleavage site is in the sequence between amino acids 37 
and 43, leading to the production of Aβ fragments of different sizes (42).    
 
1.2.2.3. Alpha-secretase 
 
α-secretase is a membrane-bound zinc metalloproteinase found essentially at the 
plasma membrane of cells (43,44). Its characterized as a type-I transmembrane protein, 
like APP, and is involved in the non-amyloidogenic pathway APP processing (43).   
There is no consensus to define the principal α-secretase involved in APP 
processing. Some ADAM (a disintegrin and metalloproteinase) family members have α-
secretase activity and have been proposed to be the main α-secretase in APP processing 
(43,44). These include ADAM9, ADAM 10 and ADAM17. Studies points to ADAM10 
being the main α-secretase at the cell surface, but depletion of any of the ADAM proteins 
will decrease Aβ formation. Due to these findings, functional redundancy in α-cleavage 
leads to the theory that there is likely to be more than a single α-secretase involved in APP 
processing (43,44).  
α-secretase is allegedly found in non-rafts portions of the cell membrane 
(18,33,44). Despite APP being associated with lipid rafts, α-secretase activity accounts for 
more than 90% of APP processing. This can be explained by the existence of two cellular 
pools of APP, one directed to lipid rafts and the other associated with the non-raft parts of 
the membrane (14,44,59). 
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Alongside APP, other substrates are cleaved by α-secretases. All kinds of type I 
transmembrane proteins are substrates for α-secretases, such as Tumor necrosis factor α, 
the pion protein, Notch receptors and ligands or cadherins (42,44). 
 
1.2.3. Aβ clearance 
 
As discussed above, Aβ peptides can be found in healthy patients, and it is 
presumed to have a physiological role (29). As such, it is normal that the brain has 
mechanisms to eliminate Aβ peptides, which have a half-life of approximately 8h in human 
brains (29). 
 Aβ peptides can be eliminated by various ways: proteolytic degradation by action 
of enzymes; clearance mediated by receptors in neuronal cells (neurons, glia cells); 
through the Blood Brain Barrier (BBB) or through the Interstitial fluid (ISF) drainage 
pathway (Figure 9) (6,29).  
 Aβ clearance is mediated by receptors in neuronal cells or even on endothelial cells 
that form the BBB. The receptors that seem to be involved are likely to be ApoE-
lipoprotein receptors (LDLR family members) which are widely present in the cell types 
previously reported (6,29). Aβ peptides are then internalized together with the receptors in 
endosomes and delivered to lysosomes where they can be degraded (29). This method has 
proved to be reliable to eliminate the Aβ peptides, but is possible that it could lead to toxic 
intracellular accumulation of those peptides in multivesicular bodies, endosomes and 
lysosomes (29).  
 Another method of Aβ clearance is by proteolytic degradation via the action of Aβ-
degrading enzymes (6,29). The enzymes are produced and expressed in both neurons and 
glia cells and in to some extent in the cerebral vasculature (29). Several enzymes have been 
associated with this process, and Neprilysin and Insulin-Degrading enzyme (IDE) are 
among the most studied ones (6,29). 
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1.2.4. APP phosphorylation 
 
Among all the regulatory mechanisms in cell biology, protein phosphorylation is 
the major one, it is involved in all kinds of cell functions (45,62). Typically, a protein 
kinase transfers a phosphate molecule from an ATP molecule to a protein. This will lead to 
alterations in the conformation of the protein, as well as its function. To revert to its 
original state, the phosphate molecule will be removed by the action of a protein 
phosphatase.  
Despite being a highly regulated mechanism, protein phosphorylation is altered in 
many diseases, including AD (45,62). The brain has the highest concentration of protein 
kinases and phosphatases, and it can be explained by the fact that brain functions, like 
memory, are important and dependent on protein phosphorylation. So, an abnormal 
regulation of these processes will contribute to the development of AD. 
Apart from tau protein which is found hyperphosphorylated in AD, 
phosphorylation of APP may also contribute to the progression of the disease (62). APP is 
considered to be a phosphoprotein, so is natural that it would be affected by 
phosphorylation reactions. APP levels and functions (binding, trafficking and processing) 
Figure 9 – Aβ clearance pathways in the brain. 
A Beta peptides accumulation in the brain leads to A Beta oligomerization and formation of senile 
plaques (SP). A Beta has a short half-life in the brain of humans (~8h). The major Abeta clearance 
pathways are shown: proteolytic degradation by action of enzymes (1); clearance mediated by receptors 
in neuronal cells (2) and clearance through the Blood Brain Barrier (BBB) or the Interstitial fluid (ISF) 
drainage pathway (3) (adapted from (29)). 
 
1) 
2) 
3) 
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seem to be under regulation of both protein kinases (Protein Kinase C [PKC]) and protein 
phosphatases (Ser/Thr protein phosphatases type 1 [PP1]). Within its intracellular domain, 
APP presents 8 possible phosphorylation sites (Figure 10). In patients with AD, seven of 
those APP possible phosphorylation sites (Figure) were demonstrated to be phosphorylated 
in vivo and in vitro: Tyr653, Ser655, Thr668, Ser675, Tyr682, Thr686 and Tyr687 (in 
APP695 numbering) (33,49).  
 
 Regarding AD, patients exhibit an upregulation of APP βCTFs phosphorylated at 
Thr668. It is also found phosphorylated in rat brains and in several cell lines. 
Phosphorylation of APP at Thr668 is normally detected in the brain, and is associated with 
a role in APP metabolism, more specifically in making APP more favorable to be cleaved 
by BACE1 and forming Aβ fragments (49). Phosphorylation at Thr668 seems also 
necessary to form the interaction of AICD and Fe65, allowing AICD to be internalized into 
the nucleus and inducing neurotoxicity (64). Other putative roles of phosphorylation on 
this residue are related with regulation of neurite extension, of APP axonal trafficking and 
attenuation of APP cleavage by caspases. Both phosphorylated APP and CTFs at Thr668 
are found at neurites within growth cones, while the dephosphorylated APP is found at its 
Figure 10 – Schematic representation of APP695 phosphorylation sites. 
The eight putative phosphorylated sites in the APP intracellular domain and the two phosphorylated Ser 
residues in APP ectodomain are shown.  
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highest in the neuronal cell body. Study of APP Thr668 phosphorylation can be made by 
replacing that residue with an Alanine or a Glutamate, to mimic both non-phosphorylated 
and phosphorylated state, respectively. 
Another APP intracellular site, Tyr687, is also found phosphorylated in AD, and it 
seems to be involved in the subcellular localization of APP (62). Phosphorylation at 
Ser655 seems to regulate APP binding and APP secretory trafficking, while 
phosphorylation at Tyr682 promotes interactions between APP and Shc adapter proteins. 
Little information is found concerning the remaining APP intracellular phosphorylation 
sites (62).  
Regarding the APP ectodomain, Ser198 and Ser206 are sites suffer 
phosphorylation, but they do not seem to be involved in AD related events (Figure 10) 
(65).  
 
1.2.5. APP and APP fragments functions 
 
The normal function of full-length APP is still unknown, but diverse studies 
suggest a role in synaptogenesis, neurite outgrowth, synaptic plasticity, regulation of 
neuronal survival, cell adhesion and in learning and memory processes (26,57). Another 
possible function of the full-length APP is that it can act as a cell surface receptor, but until 
now, no ligand nor related signaling pathway have been discovered (26,57).  
Since its synthesis until it reaches the plasma membrane, APP goes through a lot of 
co- and post-translational modifications, such as phosphorylation, N- and O-glycosylation 
and tyrosine sulfation. However, it is on its way to and at the plasma membrane that APP 
is processed by endoproteolytic secretases into smaller and distinct fragments (11,21). The 
proposed functions of full-length APP seem to result from the sum of all related functions 
of the various APP peptidic fragments.  
sAPPα seems to have a neuroprotective function, promoting neurite outgrowth, 
synaptogenesis, regulating calcium homeostasis and involvement in cell adhesion. 
However, sAPPβ does not have the neuroprotective effects of sAPPα, having instead 
functions related to neuronal cell death and stimulation of axonal pruning. The intracellular 
CTFs of APP do not have a specific function, but they have the ability to bind to several 
different proteins that will bind to effector proteins. AICD was shown to act as a 
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transcriptional factor. It is involved in a lot of functions that vary from cell migration and 
signaling to axonal transport and apoptosis due to the presence of a motif that will interact 
with a lot of adaptor proteins that will modulate all the cited functions (44,57). Upon its 
formation, AICD interacts and activates the nucleocytoplasmic adaptor Fe65 so it can bind 
with Tip60 and can enter the cell nucleus, exerting an effect at the level of the cell genome. 
It has been verified that AICD has transactivation activity regarding a vast group of genes 
like APP, BACE1, LRP1, EGFR, neprilysin and p53 (43,44). The fact that APP and 
BACE1 expression are regulated by AICD provides information supporting a feedback 
mechanism whereby AICD regulates the processing of its precursor (44). 
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2. Aims of the dissertation 
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Alzheimer’s disease (AD) is a complex neurodegenerative disorder characterized by a 
progressive loss of mental functions and reduction of the ability to perform simple daily 
activities. AD has two major histopathological hallmarks: extracellular senile plaques and 
intracellular NTFs. The Aβ peptide is the main component of the SP and is produced due 
to cleavage by β- and γ-secretases of the Amyloid Precursor Protein (APP). Aβ 
pathological levels seem to be altered when phosphorylation reactions occur in Threonine 
668 of the APP. Several protein complexes seem to interact with APP, like the trimeric 
complex APP/PP1/Fe65. PP1 is the central phosphatase involved in dephosphorylation of 
APP and it was shown to bind with both APP as well as the adaptor protein Fe65 in a 
trimeric complex involved in APP processing. In the latter tricomplex, phosphorylation at 
APP Thr668 was shown to be an important regulatory event. 
 
In this work the hypothesis that APP, via its interaction within different protein 
complexes, regulates Aβ production will be tested.  
 
To support this hypothesis, the specific objectives will be: 
 To characterize the APP Interactome; 
 To construct APP Wild Type and Swedish Thr668 phosphomutants (Thr668A and 
Thr668E) thus mimicking both dephosphorylated and phosphorylated states; 
 To optimize cell transfection with APP Thr668 phosphomutants; 
 To study the effects of APP phosphorylation at Thr668 (mimicked by APP Wt and 
Swe Thr668 phosphomutants) regarding Aβ processing;  
 To co-localize APP Thr668 phosphomutants with Fe65 and PP1γ. 
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3. Materials and Methods
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3.1. Cell Culture 
All methods involving cell culture and manipulation were performed using a class II air 
flow cabinet. 
 
3.1.1. Culture, growth and maintenance of SH-SY5Y cell line 
Due to being human derived cells, SH-SY5Y cell line was chosen as the model for all 
the procedures involving cells. SH-SY5Y human neuroblastoma cells are derived from the 
SK-N-SH cell line, established originally from a metastatic bone tumor biopsy (66). 
SH-SY5Y cells were grown and maintained in 10% fetal bovine serum (FBS) Minimal 
Essential Medium (MEM)/F12 (1:1) with 0.5mM L-glutamine, 100 U/mL penicillin and 
100 mg/mL streptomycin. 
Cells were maintained in an incubator at 37ºC with 5% CO2/95% air and 95% 
humidity. When cells reached about 70-80% of confluence, they were passaged or used for 
experimental procedures. Standard laboratory procedures were used as previously 
described (62). 
 
3.1.2. Transient transfection 
SH-SY5Y cells were transfected with APP-GFP constructs using a cationic lipid 
reagent-mediated method (Lipofectamine 2000 reagent). The day before transfection, cell 
were plated on a 6-well plate with complete DMEM Medium.  
On the next day, each cDNA and Lipofectamine 2000 were separately diluted in 
DMEM medium (serum free) for 5 min. The solution with cDNA was mixed in the 
Lipofectamine 2000 solution and left for 20 min at RT for DNA complexes to form. This 
mixture was then added to the medium of the respective plates of SH-SY5Y cells. The 
plates were then incubated at 37ºC and 5% CO2 for 8h. After that period, the DMEM 
medium (serum free) was discarded and new complete DMEM Medium was added. 
 
3.2. Western Blot 
Western Blot (WB) is a multistep technique for detection and characterization of 
proteins, widely used in experimental procedures. First, samples need to be collected and 
prepared, then separated on an electrophoresis gel and lastly transferred onto a 
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nitrocellulose membrane. Antibodies against the protein of interest will be added to the 
membrane, incubated, detected and finally analyzed (67).  
 
3.2.1. Sample collection 
Cell medium was collected into microtubes, and cells were first washed with PBS, and 
then harvested with 200 μL of 1% Sodium Dodecyl Sulfate (SDS). SDS is a strong and 
ionic detergent used to solubilize lipids and proteins in cell membranes. This leads to cell 
lysis by the formation of pores within the membrane.  
Cell lysates were then collected and put on ice, boiled for 10 min and later sonicated 2 
times for 3 seconds to homogenize the samples. All samples were stored at -20ºC before 
any experimental procedures.  
 
3.2.2. Determination of protein concentration 
Protein content quantification of cellular lysates was carried out using the BCA Protein 
Assay (Pierce). This assay combines the reduction of Cu2+ to Cu+ by cell proteins in an 
alkaline medium with a sensitive colorimetric detection of Cu+ cation with the use of a 
solution containing bicinchoninic acid (BCA). The purple-colored product is the result of 
the reaction between two molecules of BCA with one Cu+ ion. This complex is water 
soluble, exhibiting a strong absorbance at 562 nm that is linear with increasing protein 
concentration (67). The standards were prepared in a 96-well plate, as described in Table 3, 
and final volume of each well was equal to 25 uL. The procedures used are those well 
established in the laboratory (62). 
 
Standard BSA(μl) 10% SDS (μl) Protein Mass (μg) 
P0 - 25 0 
P1 1 24 2 
P2 2 23 4 
P3 5 20 10 
P4 10 15 20 
P5 20 5 40 
 
Table 3 – Protein Standards used in BCA protein Assay method 
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A microtube was prepared for every sample, with 5ul of each sample plus 20ul of the 
solution in which the sample was collected (1% SDS). After preparation of both standards 
and samples, the plate was incubated for 30 minutes at 37º C with 200 ul of working 
reagent (50 parts of reagent A to 1 part of reagent B). After incubation, the plate was 
cooled at RT for 5 minutes and then the absorbances were measured at 562 nm. A standard 
curve was made by plotting the Optical Density (O.D.) value for each BSA standard 
against its corresponding concentration, which was then used to determine the protein 
concentration of each sample. Both standards and samples were prepared in duplicate.  
 
3.2.3. SDS-Polyacrylamide Gel Electrophoresis 
SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) is an analytical technique that 
allows the separation and characterization of proteins and peptides of a sample mixture in a 
polyacrylamide gel by application of an electrical current. SDS is as anionic detergent able 
to denature proteins by wrapping around their polypeptide backbone. This will confer a 
negative charge to the protein in proportion to its length, and so, sample proteins are 
separated according to their molecular weight and negative net charge (67). 
Samples were subjected to a 5-20% gradient SDS-PAGE in a Hoefer electrophoresis 
system. This denaturing gel is used because it allows a separation of proteins based solely 
on their molecular weight. It consists of two similar gels, but with different polyacrylamide 
concentrations: the resolving gel (bottom) has a higher concentration of polyacrylamide 
than the stacking gel (top) (Table 4). 
A loading buffer (LB) was added to the samples before loading onto the gel. This 
loading buffer consists of Glycerol, SDS. β-mercaptoethanol and bromophenol blue. 
Glycerol allows the sample to stay in the wells by increasing the sample density; SDS 
covers the inherent charge of the sample proteins; β-mercaptoethanol breaks the disulfide 
bonds that are present on the tertiary and quaternary protein structures; and the 
bromophenol blue is a dye needed to track the progression of the sample in the gel (67).  
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Reagents Stacking Gel Resolving Gel 
3,5% 5% 20% 
Water 13.83 mL 18.59 mL 7.34 mL 
Acrylamide (29:1) 1.75 mL 3.75 mL 15 mL 
LGB (4X) - 7.5 mL 7.5 mL 
UGB (5X) 4 mL - - 
10% SDS 200 uL - - 
10% APS 200 uL 150 uL 150 uL 
TEMED 20 uL 15 uL 15 uL 
 
Electrical current is applied to the gel for approximately 4 hours so it can enable the 
separation of the sample proteins. After gel separation, proteins are transferred 
electrophoretically onto a nitrocellulose membrane so that all proteins can be immobilized 
at their relative positions at the time point when the gel run was stopped. 
 
3.2.4. Western Blotting Analysis 
A wide number of antibodies were used to detect the protein of interest by 
immunological and chemiluminescent protein detection (Table 5). 
 
TARGET PRIMARY ANTIBODY SECONDARY ANTIBODY 
AΒ N-TERMINAL 
6E10 
Dilution 1:1000 
Horseradish Peroxidase 
conjugated α-mouse IgG 
Dilution 1:5000 
APP C-TERMINAL 
Anti-C-Terminal 
Dilution 1:1000 
Horseradish Peroxidase 
conjugated α-rabbit IgG 
Dilution 1:5000 
Β-TUBULIN 
Anti-β3-tubulin 
Dilution 1:1000 
Horseradish Peroxidase 
conjugated α-mouse IgG 
Dilution 1:5000 
Table 4 – Stacking and resolving gel compositions for one SDS-PAGE system (1.5mm of thickness)  
 
Table 5 – Antibodies used to detect the proteins of interest 
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Following transfer, the nitrocellulose membrane was hydrated with 1x TBS for 10 min, 
followed by blocking with 3% BSA in 1x TBS-T. This step is necessary for the blocking of 
possible non-specific binding-sites. Afterwards, the membrane was incubated with an 
unlabeled primary antibody (that will bind to the target protein) for 4 hours at RT, with 
agitation, followed by an ON incubation at 4º C. The membrane was then washed 3 times 
with 1x TBS-T (10 min each), incubated with the secondary antibody coupled with 
horseradish peroxidase (HRP) for 2 hours, and washed again 3 times with TBS-T for 10 
minutes each.  
For protein detection, the nitrocellulose membrane was then incubated with the 
enhanced chemiluminescence (ECL) reagent or with Limunata Crescendo in a dark room, 
for 1 and 5 minutes, respectively. This method relies on the oxidation of cyclic 
diacylhydrazide luminal that will produce light. The membrane was subsequently exposed 
to autoradiography films (Kodak) in X-ray film cassette, for different periods of time 
depending on the protein of interest. Finally, the films were developed and fixed with the 
appropriate solutions (Kodak) as specified by the manufacturer. 
 
3.2.4.1. Membrane stripping 
Proteins with similar molecular weights (KDa) can be visualized in the same blot with 
the method of membrane stripping in between the immunodetections.  
A stripping solution PH 6.7 containing Tris Base and SDS was prepared and then 
mixed with β-Mercaptoethanol. After hydration of the nitrocellulose membranes with 1x 
TBS, the stripping solution previously prepared was added to the membrane, at 37ºC for 30 
min with agitation. The stripping solution was then discarded and the membrane washed, 
first 3 times with 1x TBS-T and finally with distillated water. The membranes were left to 
dry at room temperature.  
To confirm the stripping, membranes were first rehydrated with 1x TBS and then 
blocked with 5% BSA in 1x TBS-T solution for 1 hour. After, membranes were incubated 
with the secondary antibody and developed with ECL reagent, Luminata Crescendo. 
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3.2.4.2. Ponceau S staining 
The nitrocellulose membrane was first incubated in a previously prepared Ponceau S 
solution during a short time (between 5 and 10 min) and then washed with deionized water 
to make the bands in the membrane more clearly visible. The membrane was scanned in a 
GS-800 calibrated imaging densitometer in order to evaluate equal gel loading. Lastly, the 
membrane was extensively washed with 1x TBS-T to remove the staining. The regions of 
interest of the membrane were used as a loading control. 
 
3.2.5. Aβ-SDS-Polyacrylamide Gel Electrophoresis (Aβ-SDS-PAGE) 
Separation of Aβ peptides is achieved by the use of a urea version of the Bicine/Tris 
SDS-PAGE. The use of urea will induce conformational changes in Aβ peptides, which 
differ in one or two amino acids. With this method, those Aβ peptides can be easily 
separated (68–70). 
Cell medium samples were first immunoprecipitated to collect Aβ peptides. The 
immunoprecipitation was carried out using Dynabeads® Protein G (Invitrogen) magnetic 
beads. This will allow for a fast and efficient collection of our target protein and eliminate 
background since it will decrease the non-specific binding of proteins. The primary 
antibody (6E10) is added to the Dynabeads® Protein G. During a short incubation, the 
antibody will bind to the beads. Afterwards, the tube with the beads is placed on a Dynal 
magnet that will allow the capture of the beads with the antibody so that the supernatant 
can be easily removed. The beads were then stored in PBS 0,1% BSA, 0,02% NaN3 at 4º. 
To cell medium samples (800ul), 200 ul of 5-fold concentrated IP detergent buffer 
(10% Nonidet P-40, 10% sodium deoxycholate, 10% SDS, 5M NaCl, 1M HEPES, one 
tablet of Roche Complete Protease Inhibitor Cocktail Mini per 2mL of final volume, pH 
adjusted to 7.4 with NaOH) were added. To this 25ul of activated and covalently coupled 
6E10 beads were also added, and samples were incubated under rotation for 15h at 4º C. 
Beads were later washed 3x with PBS 0,1% BSA for 5 minutes each; once with 10mM 
Tris-HCL (pH 7.5). Bound Aβ peptides were then eluted by heating the sample to 95ºC for 
5 min in 25ul of sample buffer (0,36M bis-Tris, 0,16M Bicine, 1% SDS, 15% sucrose and 
0,0075% bromophenol blue). Beads were immobilized for 2 minutes and the supernatant 
with the Aβ peptides transferred to new tubes.  
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Immunoprecipitated samples were resolved on 12% Bicine/Tris gels containing 8M 
urea. Synthetic Aβ peptides (Aβ1-37, Aβ1-38, Aβ1-39, Aβ1-40 and Aβ1-42 by Annspec) 
were run in a different and parallel well with the purpose of identifying the different Aβ 
peptide species. A protein loading control (Precision Plus Protein® All Blue Standards) 
was also loaded. After gel separation, Aβ peptides were transferred under semidry 
conditions onto a methanol-activated Polyvinylidene Fluoride (PVDF) membrane so that 
all gel proteins can be immobilized at their relative positions at the time point when the gel 
run was stopped. Membranes were then washed with H2Odd and boiled for 3 minutes in 
PBS using a microwave oven. Blocking was performed for 1h at RT with Amersham 
ECL® Prime Blocking Reagent. After washing 3x with PBS-T, a primary antibody (6E10) 
was added to the membrane, incubated for 1h at RT, washed again 3x with PBS-T and 
incubated with a secondary antibody (MAB2) for 1h. The PVDF membrane was then 
incubated with Streptavidin-biotinylated horseradish peroxidase complex (GE Healthcare) 
for 1h at RT. Aβ peptides were visualized in the membrane using the LI-COR Odyssey Fc 
device after a short incubation with Amersham ECL® Start Western Blotting Detection for 
5 minutes.  
 
3.2.6. Bioinformatics tools 
A wide set of bioinformatics tools were used: Protein-Protein interactions databases 
(UniProt, IntAct); web resources to draw protein networks (SPRING); and web resources 
to obtain information about protein properties (PANTHER). The FinchTV software was 
used to confirm the cDNA mutations. 
 
3.3. Immunocytochemistry 
Immunocytochemistry is a laboratory technique used to see proteins in cells. 
Proteins are visualized with the help of biomolecules capable of specifically binding the 
protein of interest; normally the biomolecule is an antibody linked with a reporter, which 
can be a fluorophore or an enzyme. The reporter will produce a signal (fluorescence or 
color) that is detectable with the use of an appropriate microscope that depends on the 
reporter type (71). 
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 Immunocytochemistry was performed in order to visualize APP phosphomutants 
tagged with GFP as well as the proteins Fe65 and PP1γ. Cells were first plated and 
transfected into glass coverslips (15mm) for 24h. Cells on the coverslips were then fixed 
with a solution of 4% Paraformaldehyde (PFA) for 20 minutes at RT, and washed 3x with 
PBS to remove the fixing reagent. Following fixation, cells were first permeabilized with 
0.2% PBS-Triton for 10 minutes, washed 3x PBS, and then blocked with a 3% BSA/PBS 
solution for 1h at RT.  
Following those steps, cells were incubated with a primary antibody against the 
proteins of interest for 2h on humidified conditions (Table 6). The primary antibody is 
diluted in the blocking solution (3% BSA/PBS). Cells were washed 3x with PBS and then 
incubated with the fluorescently-labelled secondary antibodies diluted in 3% BSA/PBS for 
1h in a dark environment (Table 6). Coverslips were washed again 3x PBS and 1x with 
distillated water. Following the washing steps, a drop of mounting medium (Vectashield 
without DAPI) was added to each slide.  
Fluorescence microscopy was performed using an LSM510-Meta confocal 
microscope (Zeiss), and the argon laser lines of 405 nm, 488 nm and 561 nm DPSS laser 
were used. Pictures were acquired using the Zeiss LSM 510 4.0 software. 
 
Target Primary Antibody Secondary Antibody 
Fe65 
Anti-Fe65 (Mouse) 
Dilution: 1:250 
AlexaFluor 594 (Mouse) 
Dilution: 1:300 
PP1γ 
Anti-PP1γ (Rabbit) 
Dilution: 1:500 
AlexaFluor 405 (Rabbit) 
Dilution: 1:200 
 
 
 
Table 6 – Primary and Secondary antibodies used in immunocytochemistry  
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4. Results and Discussion 
 
 41 
 
4.1. APP Interactome 
 
Proteins interactomes are a crucial tool to understand the network of possible 
interactions between different proteins. Protein-protein interactions are the key to 
understanding cellular processes, thus interactomes are constructed to provide a useful 
insight into the mechanism of protein functions. Interactomes are dynamic: many 
interactions occur for a particular time in a protein life; others may be transient or can only 
happen under specific cellular contexts (72–74).  
In order to construct the APP interactome, protein-protein interactions were obtained 
by using a primary database that contains protein-protein interactions. A large number of 
databases are available, but the UniProt database was chosen (75). The UniProt database 
relies on a much bigger database (IntAct) to highlight the protein-protein interactions with 
a higher number of confirmation experiments. From the 403 interactions with APP 
reported in IntAct, UniProt highlighted 38 main interactions with a minimum of 2 
validation experiments (Table 7). 
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PROTEIN 
NUMBER OF 
VALIDATION 
EXPERIMENTS 
PROTEIN 
NUMBER OF 
VALIDATION 
EXPERIMENTS 
APP 
ITSELF 
104 MED12 2 
APBA1 3 MT-ND3 2 
APBB1 5 NEFL 2 
APBB2 2 NF1 3 
APLP1 2 NGFR 2 
APLP2 2 PCBD1 2 
APOA1 5 PCOLCE 3 
BLMH 2 PDIA3 3 
CALR 3 PIN1 2 
COL18A1 2 PRNP 3 
CTSD 2 PSEN1 6 
FLOT1 5 SHC1 5 
FOS 3 SHC3 2 
GPR3 2 SLC40A1 5 
HOMER3 3 SPON1 3 
HSD17B10 4 TGFB1 3 
ITM2A 3 TGFB2 7 
JUN 2 TNFRSF21 3 
MAP3K5 2 TP53BP2 3 
MAPT 9   
 
In order to have a better visualization of the network between all the protein-protein 
interactions listed on the table above, a web resource (STRING) with proper characteristics 
was utilized. The resultant image network is seen on Figure 11. 
Table 7 – APP interacting proteins  
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Each protein-protein interaction has a numerical score: the higher the score, the 
higher the confirmation with respect to validating the interaction. On the image network 
obtained with STRING, that score can be analyzed by the intensity of the bands between 
proteins.  
Using another web resource (PANTHER), the list of protein-protein interactions 
was analyzed to infer the relationship, function and signaling pathways of the interactions 
(Figure 12 and 13). 
Figure 11 – Network of APP interacting proteins 
The 38 APP interacting proteins are represented by circles, and thick lines correspond to interactions that 
are presented in the public databases. Thicker lines correspond to interactions with higher number of 
validated experiments.  
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Figure 12 – Molecular functions of APP interacting proteins 
The majority of APP interacting proteins have functions of binding, catalytic and receptor activity. Any 
APP interacting protein can have more than one function.  
 
Figure 13 – Signalling pathways of APP Interacting Proteins  
Several signalling pathways are represented in the figure. Of relevance to AD are the Alzheimer’s 
Disease-amyloid secretase and the Alzheimer’s disease presinilin pathways. Any APP interacting protein 
can have more than one signalling pathway.  
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MOLECULAR FUNCTION 
NUMBER 
OF 
GENES 
LIST OF PROTEINS 
BINDING 15 
CALR, TGFB2, JUN, TP53BP2, APBB1, 
APOA1, TGFB1, APP, FOS, HOMER3, 
MED12, PCOLCE, SHC1, APBB2, SHC3 
CATALYTIC ACTIVITY 10 
HSD17B10, PDIA3, NF1, APOA1, CTSD, 
PIN1, PSEN1, MAP3K5, PCBD1, PCOLCE 
RECEPTOR ACTIVITY 6 
COL18A1, GPR3, TNFRSF21, NGFR, 
PCOLCE 
TRANSPORTER ACTIVITY 4 COL18A1, APOA1, PCOLCE 
NUCLEIC ACID BINDING 
TRANSCRIPTION FACTOR 
ACTIVITY 
3 JUN, FOS, MED12 
ENZYME REGULATOR ACTIVITY 3 NF1, APOA1, PCOLCE 
STRUCTURAL MOLECULE 
ACTIVITY 
2 COL18A1, NEFL 
PROTEIN BINDING 
TRANSCRIPTION FACTOR 
ACTIVITY 
1 MED12 
 
With the help of the bioinformatics tools (STRING, PANTHER), a lot of information 
can be obtained about the APP interacting proteins. The majority of the proteins that 
interact with APP possess catalytic or receptor activity, or are related to binding processes 
(Table 8). It is also observed that some APP interacting proteins are involved in signaling 
pathways related with Alzheimer’s disease, like the Alzheimer’s Disease-amyloid secretase 
and the Alzheimer’s disease presinilin pathways (Figure 13). The other types of signaling 
pathways related with proteins that interact with APP shows the difficulty that is 
establishing a function to the APP. 
So, a better understanding of APP interactions is obtained by its interactome. Studying 
predicted interaction networks can provide new information and future experimental 
research strategies. With particular interest for this thesis and future work are the proteins 
that interact with APP on the residues Thr668 and Tyr687 (Figure 14). 
Table 8 – List of APP interacting proteins and respective functions 
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Figure 14 – Schematic representation of APP Thr668 and Tyr687 residues and proteins regulated 
by its phosphorylation 
Phosphorylation of APP Thr668 and Tyr687 is involved in the regulation of several cell processes. When 
phosphorylated, APP interacts with different proteins: phosphorylation of Thr668 is shown to influence 
the interaction of Fe65, Pin1 and Shc1 with APP, leading to changes in APP processing; several other 
proteins (Fe65, X11, Shc1, Grb2, JIP-1, and KLC) interact with APP when Tyr687 is phosphorylated, 
modulating the metabolism and trafficking of APP .  
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4.2. Construction of WT and Swe Thr668 A/E APP695-GFP cDNAs 
 
Since APP processing involves protein-protein interactions that are highly regulated by 
phosphorylation, the production of mutants at specific APP of phosphorylation sites, will 
allow us to study the role of the residues on the processing, metabolism and other 
physiologically relevant processes. The first step of this thesis was to construct APP 
Thr668 phosphomutants. The isoform used was APP695 due to its relevance in AD 
neuropathology. 
APP Wild Type (Wt) and APP with Swedish mutation (Swe) were already available in 
the laboratory. The Swedish mutation is the only known APP mutation near the β-secretase 
cleavage site. In fact, it is a double mutation (substitution of lysine595 and methionine596 
to asparagine and leucine, respectively). This mutation is known to make APP more 
available to BACE1, increasing the production and secretion of Aβ peptides.  
Both cDNAs (Wt and Swe) were already fused with a reporter gene coding for the 
Green Fluorescence Protein (GFP) and inserted in a mammalian expression vector 
(pRc/CMV – Invitrogen) (Figure 15).  
 
 
 
Figure 15 – Schematic representation of a mammalian expression vector with inserted APP-GFP 
cDNA 
APP cDNAs with the specific mutations on Thr668 (Thr668 to 668A; Thr668 to 668E) were fused with a 
reporter gene coding for GFP and inserted into the pRc/CMV mammalian expression vector.  
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From these two cDNAs, 4 new phosphomutants were constructed [from Thr668 to 
Alanine (A) and from Thr668 to Glutamate (E)]. Alanine is a non-phosphorylatable and 
non-polar residue, blocking APP phosphorylation at that residue. Glutamate, on the other 
hand, is also a non-phosphorylatable residue, but is negatively charged, and due to its size 
and charge it mimics to some extent the presence of a phosphate group at that position on 
APP (76,77).  
All the phosphomutants were produced by site directed mutagenesis PCR (QuikChange 
II Site-Directed Mutagenesis Kit). This in vitro method allows site-specific mutations in 
any double-stranded DNA plasmids. Following site directed mutagenesis, APP-GFP 
phosphomutants were amplified in bacterial systems (E. coli XL-1 blue competent cells) 
by transformation procedures. Plasmid cDNAs were extracted from the resultant bacterial 
cultures, and PCR products were subjected to sequential digestion with the endonucleases 
SmaI (produces blunt terminals) and HindIII (produces “sticky” terminals). The resultant 
products were resolved on a 0.5% agarose gel, extracted from the agarose gel and purified 
with a Gel Extration kit (QIAgen). If correctly prepared, the vector with cDNA, when 
digested by endonucleases, yields one band of 5.5 Kb (linearized form of the vector) and 
another band of around 2 Kb that corresponds to APP-GFP. For the phosphomutants 
cDNA plasmid, two bands of around 5.5 and 2 Kb were expected and obtained. 
Subsequently, to confirm the correct mutation of the cDNAs phosphomutants, a 
small sample of each cDNA (80-100 ng/ul) was sent for sequencing (Lightrun 
Sequencing), along with 5uM of primers. The nucleotide sequences of Wt and Swe APP 
Thr668 point mutations were confirmed by DNA sequencing using the FinchTV software, 
the correct insertion of APP in the open reading frame next to the GFP coding sequence 
was likewise confirmed. Parts of the sequences obtained are presented in Figures 16 and 
17.  
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Figure 16 – Confirmation of Wt APP Thr668 mutations by DNA sequencing 
From an original WT APP Thr668 cDNA, point mutations were obtained by site directed mutagenesis 
PCR. Threonine (ACC codon) was mutated into an Alanine (GCG codon) producing APP 668A (top). 
Threonine was also mutated into a Glutamate (GAA codon) producing APP668E (bottom). Images 
obtained with the use of FinchTV software. 
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APP-GFP constructs were also expressed in SH-SY5Y cells using transient transfection 
with Lipofectamine, and analyzed by fluorescence microscopy. All APP-GFP constructs 
expressed APP tagged with GFP (Figure 18).  
Figure 17 – Confirmation of Swe APP Thr668 mutations by DNA sequencing 
From an original Swe APP Thr668 cDNA, point mutations were obtained by site directed mutagenesis 
PCR. Threonine (ACC codon) was mutated into an Alanine (GCG codon) producing Swe APP 668A 
(top). Threonine was also mutated into a Glutamate (GAA codon) producing Swe APP 668E (bottom). 
Images obtained with the use of FinchTV software. 
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Figure 18 – Expression of APP-GFP constructs in SH-SY5Y cells 
SH-SY5Y cells were transfected with the constructed APP-GFP cDNAs and its expression observed by 
fluorescence microscopy. All cDNA were expressed. Legend: SH-SY5Y cells transfected with a) Wt-
APP Thr668; b) Wt-APP 668A; c) Wt-APP 668E; d) Swe-APP Thr668; e) Swe-APP 668A; f) Swe-APP 
668E. 
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4.3. Optimization of the transfection method 
In order to optimize SH-SY5Y cells transfection, two transient transfection methods 
were tested. Cells were plated in a 6-well plate, and transfected on the next day with Wt 
APP-GFP, Swe APP-GFP and APP T668A/E-GFP cDNAs, using the Lipofectamine 
method and the TurboFect TM reagent. Lipofectamine is a cationic liposome based reagent 
that will introduce foreign cDNA into the cells, increasing its expression. TurboFect TM is 
a cationic polymer that forms complexes with cDNA so that it can be integrated into the 
cell. Both methods are widely used in the laboratory. 
The expression levels of APP-GFP from both transfection methods were evaluated first 
by fluorescence microscopy (Figure 19 and 20) and then by immunoblot analysis of cell 
lysates using the anti-APP 22C11 antibody that will bind to the N-Terminus of the APP 
(Figure 21). 
 
 
 
Figure 19 – Confirmation of APP-GFP constructs transfection with Lipofectamine 
SH-SY5Y cells were transfected with the constructed APP-GFP cDNAs with the Lipofectamine reagent 
and its expression observed by fluorescence microscopy. All cDNA was expressed. Legend: SH-SY5Y 
cells transfected with a) Wt-APP Thr668; b) Wt-APP 668A; c) Wt-APP 668E; d) Swe-APP Thr668; e) 
Swe-APP 668A; f) Swe-APP 668E. 
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Figure 20 – Confirmation of APP-GFP constructs transfection with TurboFect TM 
SH-SY5Y cells were transfected with the constructed APP-GFP cDNAs with the TurboFect TM reagent 
and its expression observed by fluorescence microscopy. All cDNA was expressed. Legend: SH-SY5Y 
cells transfected with a) Wt-APP Thr668; b) Wt-APP 668A; c) Wt-APP 668E; d) Swe-APP Thr668; e) 
Swe-APP 668A; f) Swe-APP 668E. 
 
Figure 21 – Immunoblot analysis of APP-GFP transfection in SH-SY5Y cells using TurboFect and 
Lipofectamine 
The endogenous and transfected levels of APP were visualized with the use of an anti-APP N-terminus 
antibody (22C11). Endogenous APP is shown by a black arrow; transfected APP-GFP is shown with a 
white arrow. Legend: C) Non-transfected control; Wt) Wt-APP Thr668; T668A) Wt-APP 668A; T668E) 
Wt-APP 668E; Swe) Swe-APP Thr668; T668A) Swe-APP 668A; T668E) Swe-APP 668E. 
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From the analysis of the fluorescence microscopy results, the different APP cDNAs 
were more expressed in SH-SY5Y cells transfected with the Lipofectamine method (Figure 
19). A lower number of SH-SY5Y cells seem to be transfected with the TurboFect method 
(Figure 20), leading to not so good APP cDNA expression levels when compared with 
Lipofectamine, which have a visible higher number of transfected cells.  
Lipofectamine also presents better results than TurboFect TM in the immunoblot 
results (Figure 21). Both endogenous (black arrow: ~110kDa) and transfected (white 
arrow: ~137kDa) APP levels are visible with the different transfection methods. 
Distinguishing between endogenous and transfected bands is possible because any GFP-
tagged protein will have an increase of around 27kDa in their molecular weight, as seen 
with transfected APP (white arrow: ~137 kDa). However, lysates of cells transfected with 
Lipofectamine have a stronger transfected APP band (Figure 21, white arrow) than the 
TurboFect TM, showing that with the Lipofectamine method, cells were able to express 
more APP. This is supported by the evidence collected with fluorescence microscopy, 
since with Lipofectamine, more cells were transfected and higher production of APP was 
obtained (Figure 19 and 20). Therefore, with the collected data, the Lipofectamine method 
was chosen and used in all subsequent assays. 
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4.4. Effect of APP phosphorylation at Thr668 in Aβ production 
 
APP is a transmembrane protein, which is regulated by phosphorylation by the 
action of several kinases and phosphatases. Recent studies have provided evidence of 
involvement of APP phosphorylation in Aβ processing (64,78). Of particular interest is the 
APP Thr668 residue. Phosphorylation of Thr668 at APP shows modifications of Aβ 
processing levels, but different studies do not reach a consensus: in some studies, Aβ 
processing increases (64,78); in others, the opposite results are obtained (79,80).  
In order to study Aβ processing of the Wt and Swe APP Thr668 phosphomutants, 
SH-SY5Y cells were transfected with each cDNA and transfection was confirmed by 
means of fluorescence microscopy (Figure 22). Cell medium of SH-SY5Y cells transfected 
with APP Thr668 phosphomutants were collected. Immunoprecipitation of Aβ peptides on 
collected cell medium samples was prepared, and were subsequently analyzed by Aβ-SDS-
PAGE in the presence of 8M urea. Cell medium of cells non-transfected and of cells 
transfected only with an empty GFP-vector were also collected, immunoprecipitated and 
loaded in the gel as controls (Figure 23).  
 
 
Figure 22 – Confirmation of APP-GFP phosphomutants transfection with Lipofectamine 
SH-SY5Y cells were transfected with the APP-GFP phosphomutants cDNAs using the Lipofectamine 
reagent and its expression was observed by fluorescence microscopy. All cDNA was expressed. Legend: 
SH-SY5Y cells transfected with a) Wt-APP Thr668; b) Wt-APP 668A; c) Wt-APP 668E; d) Swe-APP 
Thr668; e) Swe-APP 668A; f) Swe-APP 668E. 
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Using the conventional SDS-PAGE system, different Aβ peptides would migrate as 
a single band (4kDa). The presence of urea on the Aβ-SDS-PAGE, will prevent Aβ 
aggregation and induce Aβ specific conformational changes, affecting their molecular 
radii. Thus, Aβ peptides (4kDa) with differences in one or two amino-acids that would 
migrate in a single band in a SDS-PAGE, can be easily separated and visualized into 
different bands (Figure 23) (68–70). 
A mixture of Aβ synthetic peptides (Q1 mix: Aβ 1-37, Aβ 1-38, Aβ 1-39, Aβ 1-40 and 
Aβ 1-42) is used as control, mimicking the different Aβ peptides ratio in the human body 
(Table 9). On the Aβ-SDS-PAGE, the bigger Aβ peptides run for a longer time than the 
shorter Aβ peptides, not obeying the law of mobility/molecular weight relationship that is 
observed on SDS-PAGE. 
 
Figure 23 – Aβ production of APP-GFP phosphomutant visualized by Aβ-SDS-PAGE  
SH-SY5Y cell medium were immunoprecipitated to collect Aβ and then analysed by Aβ-SDS-PAGE. Q1 
mix with synthetic Aβ peptides (Aβ 1-37, Aβ 1-38, Aβ 1-39, Aβ 1-40 and Aβ 1-42) were used as control. 
The top and the bottom image show two obtained results.  Legend: Q1) Mix of synthetic of Aβ peptides; 
Wt) Wt-APP Thr668; T668A) Wt-APP 668A; T668E) Wt-APP 668E; Swe) Swe-APP Thr668; T668A) 
Swe-APP 668A; T668E) Swe-APP 668E; C) Non-transfected control; EV) Empty-GFP vector control. 
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Aβ-peptide Q1 mix (pg) 
1-37 30 
1-38 60 
1-39 30 
1-40 120 
1-42 60 
 
With the use of fluorescence microscopy, SH-SY5Y cells were shown to visually 
express the transfected APP-cDNAs (Figure 22). Using Aβ-C-terminal antibody (6E10) to 
the cell medium samples, one expects to see the Aβ production for the different 
phosphomutants. All phosphomutants and controls produced Aβ peptides, and more than 
one Aβ band was evident for each APP 668A/E phosphomutant (Figure 23). As 
anticipated, according to the literature, Aβ1-40 was the main Aβ peptide produced by all 
transfected and non-transfected cells (Figure 23). Other weaker bands are also observed, 
especially for the Swe APP 668A/E phosphomutants: one corresponding to Aβ1-38 and 
another equivalent to Aβ1-42. The results followed the estimated Aβ distribution: 
 
Aβ1-40 > Aβ1-42 = Aβ1-38 
 
As expected, the Swe APP 668A/E phosphomutants seem to produce more Aβ than 
normal. Aβ1-40 is the major produced Aβ peptide, but even Aβ1-38 and 1-42 appear to be 
produced in higher quantities (Figure 23). Swedish mutation of APP was proposed to make 
APP more favorable to be cleaved by BACE1, leading to higher amounts of total Aβ 
peptides, although keeping the Aβ1-40/Aβ1-42 ratio (81,82). A small increase of Aβ 
production appears to happen on the Swe APP 668A (non-phosphorylated state) in 
comparison with Swe APP 668E (Figure 23), although more studies and quantitative 
analysis have to carried out to further validate this conclusion.   
 Regarding Wt APP and its 668A/E phosphomutants, Aβ production also seems to 
be increased when compared with non-transfected controls (Figure 23). Available literature 
does not reach a consensus about the effect of Thr668 phosphorylation on Aβ production. 
Table 9 – Q1 mix of Synthetic Aβ peptides 
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Some report an increase in Aβ production (53,58), while others report a decrease or do not 
observe a connection between APP Thr668 phosphorylation and Aβ production (79,80).  
However, we show that the mimic of phosphorylated state of Wt APP Thr668 (668E) 
seems to produce higher levels of Aβ peptides (Aβ1-40 and Aβ1-38) (Figure 23, bottom). 
Again, more studies and quantitative analysis should be carried out so that this conclusion 
can be fully embraced.   
Quantitative comparisons between phosphomutants were not possible due 
immunoprecipitation not being a quantitative method. One way to solve this problem 
would be to run at the same time a SDS-PAGE with the lysates of cells used for the Aβ-
SDS-PAGE. This way, we would have a notion with respect to the total APP levels 
(endogenous plus transfected), and with that information we could extrapolate the 
transfected levels of each phosphomutant and infer a quantitative analysis of Aβ 
production. 
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4.5. Effect of APP phosphorylation at Thr668 in CTF formation 
 
Many different cleavage sites have been identified in APP. Both β- and γ-secretases 
may cleave APP at multiple sites. Considering that phosphorylation of APP Thr668 is 
supposedly involved in an increased processing by BACE1, one would expect intracellular 
βCTF to be higher for APP Thr668 phosphomutants.  
To test this hypothesis, SH-SY5Y cells were transfected with Wt APP Thr668 and 
Wt APP 668A/E phosphomutants. Transfection was conducted for 48h in order to allow 
the cells to express the phosphomutants. Non-transfected SH-SY5Y cells were used as a 
control, as well as cells transfected with an empty GFP Vector. Transfection was 
confirmed by fluorescence microscopy (Figure 24). Cell lysis was later achieved by 
addition of SDS 1%, and cell lysate samples were quantified and then loaded on a 5%-20% 
denaturing SDS-PAGE (Figure 25) 
 
 
 
 
Figure 24 – Confirmation of APP-GFP phosphomutants transfection with Lipofectamine 
SH-SY5Y cells were transfected with the APP-GFP phosphomutants cDNAs using the Lipofectamine 
reagent and its expression was observed by fluorescence microscopy. All cDNA was expressed. Legend: 
SH-SY5Y cells transfected with a) Wt-APP Thr668; b) Wt-APP 668A; c) Wt-APP 668E. 
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Western blot analysis with APP C-terminal antibody revealed, as expected, the SH-
SY5Y endogenous APP [black arrow 1) ~110kDa] and several endogenous APP fragments 
[black arrows 3) and 2) ~30 and ~50 kDa] on both controls and Wt APP-GFP 
phosphomutants (Figure 25). Three extra bands, migrating at ~120 kDa (white arrow 1), 
~40 kDa (white arrow 2) and ~35 kDa (white arrow 3) appear only in the APP-GFP 
transfected cellular lysates, and not in the controls (Figure 25). These are likely to 
correspond to APP-GFP (white arrow 1 ~137 kDa) and to β (white arrow 2 ~39 kDa) and α 
CTF-GFP (white arrow 3 ~35 kDa). As expected, differences between phosphomutants 
and controls are visible. Any GFP-tagged protein will have an increase of around 27kDa in 
their molecular weight, and this is visualized in the Figure 25 (white arrows 1,2 and 3).  
In essence, both Wt APP Thr668A and 668E seem to present stronger levels of α 
and β CTF-GFP (Figure 25, white arrows 2 and 3). It is also observed that more βCTF-
GFP is produced when compared to α-CTF-GFP, but quantitative analysis and more 
studies are required. Literature supports that β-CTFs generated by BACE1 are 
preferentially phosphorylated on Thr668 over the α-CTFs, and that CTFs of Thr668 
phosphorylated APP are elevated in AD brains (78). Our results seem to propose that 
mimic of both phosphorylated (668E) and non-phosphorylated state (668A) of Wt APP 
Thr668 can regulate the β-secretase processing of APP, increasing the levels of βCTF 
(Figure 25, white arrow 2).  
Figure 25 – Immunoblot analysis of CTF formation of Wt APP-GFP phosphomutants 
SH-SY5Y cells were transfected with Wt APP-GFP phosphomutants and cell lysates were collected and 
run on a denaturing SDS-PAGE. APP C-terminal antibody was used. Endogenous APP (black arrow 1) 
and its endogenous fragments (black arrows 2 and 3) are presented. Transfected APP-GFP (white arrow 
1) and β- (white arrow 2) and α CTF-GFP (white arrow 3) are also visible. Legend: PM) Protein Marker; 
Wt) Wt-APP Thr668; T668A) Wt-APP 668A; T668E) Wt-APP 668E; C) Non-transfected Control; EV) 
Empty-GFP vector control. 
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4.6. Immunocytochemistry of the APP/Fe65/PP1γ trimeric complex in SH-
SY5Y cells 
 
A clear relationship between APP, Fe65 and PP1γ was shown on a previous study 
(84). Fe65 is the bridging protein between APP and PP1γ, forming the trimeric complex 
APP/Fe65/PP1γ. The phosphorylation of Thr668 was also shown to be a regulatory process 
of the trimeric complex. When phosphorylated by PP1γ on Thr668, APP is made available 
for the subsequent processing events (84). Co-localization of the trimeric complex was 
found in the cell and nuclear membrane, but the three proteins are also described to be 
found in the nucleus (84). 
In order to visualize in vivo whether the APP/Fe65/PP1γ trimeric complex was 
present in SH-SY5Y cells transfected with 668A/E mutants, we decided to perform an 
immunocytochemistry and observe the co-localization of APP phosphomutants, Fe65 and 
PP1γ. 
The following images (Figure 26 and 27) represent the results obtained. 
 
 62 
 
 
 
Figure 26 – PP1 gamma, Fe65 and Wt APP phosphomutants (668A/E) co-localization in SH-SY5Y 
cells 
Wt APP-GFP phosphomutants (668A/E) appears as green, PP1 gamma as blue and Fe65 as red. Merge 
represent the co-localization image of all the 3 marked proteins. White arrow 1 represent neuronal growth 
cones, while white arrow 2 represent filopodia. The image scale is 10 um. Legend: Wt) Wt-APP Thr668; 
T668A) Wt-APP 668A; T668E) Wt-APP 668E.  
1 
1 
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By analyzing the above figures (Figure 26 and 27), it is possible to observe that 
only Fe65 (marked as red) did not show any kind of signal. That is explained by the fact 
that the available anti-Fe65 antibody was old and not working properly. A new anti-Fe65 
antibody has to be used to prove the presence of the APP/Fe65/PP1γ trimeric complex on 
cells transfected with APP 668A/E phosphomutants. 
Nonetheless, both APP phosphomutants (marked as green) and PP1γ (marked as 
blue) show a perceptible signal  in all the obtained images (Figure 26 and 27). It is possible 
to see that APP is found on the cell membrane, Golgi apparatus and endocytic vesicles, 
subcellular neuronal sites known to have higher concentrations of APP (Figure 26 and 27). 
In neurons, PP1γ is highly concentrated on dendritic spines and presynaptic terminals. 
Those subcellular locations are not visible with undifferentiated SH-SY5Y cells. However, 
PP1γ also shows expression in the nucleus (nucleolus and nucleoplasm) and in the 
cytoplasm, with exchanges between those cellular compartmens. It is possible to see on the 
obtained images (Figure 26 and 27) that PP1γ is easily found on the nucleus and also 
spread throught the cytoplasm. 
APP Thr668 phosphorylation is described as an event that will lead to the 
differentiation of neuronal cells, proved by the presence of APP in neurites and growth 
cones. Both cells transfected with APP Wt 668A/E (Figure 26) present some morfological 
Figure 27 – PP1 gamma, Fe65 and Swe APP phosphomutants (668A/E) co-localization in SH-SY5Y 
cells 
Swe APP-GFP appears as green, PP1 gamma as blue and Fe65 as red. Merge represent the co-
localization image of all the 3 marked proteins. The image scale is 10 um. Legend: Swe) Swe APP 
Thr668.  
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changes related to phosphorylation events on Thr668. On the images obtained, it is 
possible to see the appearance of growth cones (Figure 26, white arrow 1), as well as the 
presence of some filopodia (Figure 26, white arrow 2). Both Wt and Swe APP Thr668 
transfected SH-SY5Y cells present the normal morphology associated with the cell type: 
epithelial-like cells with polygonal and regular shapes and without axons and neurites 
(Figure 26 and 27, Wt and Swe). 
Unfortunately, both Swe 668A/E phosphomutants (marked as green) did not show 
any signal, and so, both PP1γ and Fe65 were also not obtained. It is critical to repeat the 
experiment with the Swe 668A/E phosphomutants so that new information can be 
acquired.  
Nevertheless, the experimental procedure here performed represent a preliminary 
study that needs to be optimized and repeated in order to confirm the physical interactions 
between APP 668A/E phosphomutants and Fe65 and PP1γ. No co-localization analysis 
was made between APP and PP1γ since the number of transfected cells was low. 
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5. Concluding Remarks and 
Future Prospects 
 67 
 
 
Phosphorylation plays an important role in all cellular functions, and is highly 
associated with APP and with AD.  Several studies imply an important role of APP Thr668 
in the development of AD, especially on APP metabolism. Recent studies also show that 
phosphorylation of this residue is needed to form trimeric complexes that are involved in 
Aβ production. According to the results obtained in this thesis, and with the use of the 
constructed Thr668 phosphomutants (668A/E), we show that APP metabolism seems to be 
related to phosphorylation on APP Thr668. There is a clear increase in Aβ production of 
Swe APP phosphomutants (668A/E), being that Aβ1-40 is the major Aβ species produced, 
followed by Aβ1-38 and Aβ1-42 (Figure 23). Wt APP phosphomutants (668A/E) also 
show some increase in Aβ production (Figure 23), as well as higher levels of β-CTF 
(Figure 25). However, more studies have to be carried out, as well as quantitative analysis 
of the visible bands. Preliminary co-localization studies of the APP/Fe65/PP1γ trimeric 
complex have shown the subcellular localization of Wt APP phosphomutants and PP1γ. 
More studies have to be realized in order to obtain a proper co-localization of the three 
proteins that form the trimeric complex. 
With this thesis, important tools (APP Interactome, APP phosphomutants, Aβ-
SDS-PAGE, Immunocytochemistry) were developed that will certainly help to prove the 
initially proposed hypothesis.  
So, in future studies, it would be of high importance to continue to study the co-
localization of different protein and complexes that were proved, by the APP Interactome 
to interact with APP, especially on the Thr668 residue. Of particular interest are both 
Fe65/PP1γ and Shc/Grb2 complexes. The first one was proved to be interacting with Wt 
APP-Thr668, and initial studies with APP phosphomutants were executed, but more are 
needed; the second complex has not yet been studied with regard to phosphorylation of 
APP Thr668.  
Other phosphorylated residues can be studied with the developed tools, with 
particular interest the Tyr687 residue on APP, since it is a residue with a high number of 
interacting proteins. 
It would also be interesting to optimize transfection conditions with other cell lines, 
like CHO or HeLa, so that a more reproducible and reliable transfection method is 
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achieved. In order to avoid the usual problems concerning transient transfection, it would 
be of interest to develop stable cell lines with the produced phosphomutants. This way, 
new additional information could also be obtained.  
Although not discussed in the scope of this thesis, subcellular localization is 
fundamental for determining APP processing, its cleavages and the peptide fragments 
produced. Namely Aβ production has been intrinsically associated with cleavages that 
occur at lipid reach sites (lipid rafts) in the plasma membrane. Nonetheless, preliminary 
studies were realized with depletion of cholesterol from the lipid rafts (data not shown). In 
the future, it will be interesting to study APP phosphomutants processing without the 
presence of lipid rafts (by cholesterol depletion using Methyl-β Cyclodextrin). From a 
neuropathological standpoint, this is particularly relevant as diseases as diabetes, for 
instance, have been associated with the onset of AD.  
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7. Appendix  
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In this section is listed the equipment and solutions used for the experiments developed in 
this thesis 
 
 Cell Culture 
 
Equipment: 
 Hera cell CO2 incubator (Heraeus) 
 Safety cabinet Hera safe (Heraeus) 
 Inverted optical microscope (LEICA) 
 Sonicator (U200S IKA) 
 Bath SBB6 (Grant) 
 Culture Plates (Corning) 
 
Reagents and Solutions: 
 Complete Medium 10% FBS MEM:F12 (1:1) 
MEM (Gibco, Invitrogen) 4.805 g 
F12 (Gibco, Invitrogen) 5.315 g 
NaHCO3 (Sigma 1.7 g 
Sodium Pyruvate (Sigma) 0.055 g 
1% Antibiotic/Antimycotic (AA) mix 
(Gibco, Invitrogen) 
10 mL 
10% FBS (Gibco, Invitrogen) 100 mL 
L-Glutamine (200 mM stock solution) 2.5 mL 
 
Adjust to PH 7.4 and to a final volume of 1000 mL in dH2O. Sterilize by filtering through 
a 0.2 μm filter and store at 4ºC. 
 
 PBS (1x) 
Dissolve one sack of BupH Modified Dulbecco’s Phosphatase Buffered Saline Pack 
(Pierce) in deionized H2O. Sterilize by filtering through a 0.2 μm filter and store at 4ºC. 
Final composition: 
Sodium Phosphatase 8 mM 
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Potassium Phosphatase 2 mM 
Sodium Chloride 140 mM 
Potassium Chloride 10 mM 
 
 Protein Concentration Determination 
 
Equipment: 
 Infinite M200 (Tecan) and I-ControlTM software 
 96 well plate (Corning) 
 
Reagents and Solutions: 
 BCA assay kit (Pierce, Rockford, IL) 
 Bovine serum albumin (BSA) (Pierce) 
 Working reagent (50 reagent A: 1 Reagent B) 
 
Reagent A: sodium carbonate, sodium bicarbonate, BCA and sodium tartrate in 0.2 N 
sodium hydroxide. 
Reagent B: 4% cupric sulfate. 
 
 
 SDS-PAGE 
 
Equipment: 
 Electrophoresis system (Hoefer SE600 vertical unit) 
 Electrophoresis power supply EPS 1000 (Amersham Pharmacia Biotec) 
 
Reagents and solutions 
 Acrylamide (29:1) 
 
 UGB (Upper Gel Buffer) (5x) 
For 900 mL of deionized H2O add 75.69 g of Tris. Mix until the solute has dissolved. 
Adjust the PH to 6.8 and the volume to 1 L with deionized H2O. 
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 LGB (Lower Gel Buffer) (4x) 
For 900 mL of deionized H2O add 181.65 g of Tris and 4 g of SDS. Mix until the solute 
has dissolved. Adjust the PH to 6.8 and the volume to 1 L with deionized H2O. 
 
 10% APS (Ammonium Persulfate) 
In 10 mL of deionized H2O dissolve 1 g of APS. 
 
 10% SDS (Sodium dodecilsulfate) 
In 10 mL of deionized H2O dissolve 1 g of SDS. 
 
 Loading Gel Buffer (LB) (4x) 
Tris Solution (PH 6.8) 1mM 2.5 mL (250 mM) 
SDS 0.8 g (8%) 
Glycerol 4 mL (40%) 
Beta-Mercaptoetanol 2 mL (2%) 
Bromophenol Blue 1 mg (0.01%) 
 
Adjust the volume to 10 mL with deionized H2O. Store in the dark at room temperature. 
 
 Tris 1M (PH 6.8) solution  
For 150 mL of deionized H2O add 30.3 g of Tris base. Adjust the PH to 6.8 and the final 
volume to 250 mL. 
 
 Running buffer (10x) 
Tris 30.3 g (250 mM) 
Glycine 144.2 g (2.5 mM) 
SDS 10 g (1%) 
 
Dissolve in deionized H2O and adjust the PH to 8.3 and the final volume to 1 L. 
 
 Western-Blotting 
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Equipment: 
 Transphor Electrophoresis unit (Hofer TE 42) 
 Electrophoresis power supply EPS 1000 (Amersham Pharmacia Biotec) 
 
Reagents and Solutions: 
 Transfer buffer (1x) 
Tris 3.03 g (25 mM) 
Glycine 14.41 g (192 mM) 
 
Mix until the solutes have dissolved. Adjust the PH to 8.3 with HCL and the final volume 
to 800 mL with deionized H2O. Just before usage add 200 mL of methanol (20%). 
 
 Immunoblotting 
 
Reagents and Solutions: 
 10x TBS (Tris Buffered Saline)  
Tris 12.11 g (10 mM) 
NaCl 87.66 g (150 mM)  
 
Adjust the PH to 8.0 with HCL and the final volume to 1 L with deionized H2O. 
 
 10x TBS-T (TBS-Tween 20) 
Tris 12.11 g (10 mM) 
NaCl 87.66 g (150 mM)  
Tween 20 5 mL (0.05%) 
 
Adjust the PH to 8.0 with HCL and the final volume to 1 L with deionized H2O. 
 
 Ponceau S solution 
Dissolve 0.1 g of Ponceau S (Sigma) in 100 mL of 5% acetic acid solution (5 mL of acetic 
acid dissolved in 95 mL of deionized H2O). 
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 Blocking solution 
5% of BSA (Bovine serum albumin, NZytech) in 1x TBS-T. 
 
 ECL solutions 
Luminata crescendo (Millipore) 
Home-made ECL 
 
 Developer and Fixer solutions (Sigma) 
 
 Membrane stripping solution 
Tris-HCL (PH 6.7) 3.76 g (62.5 mM) 
SDS 10 g (2%)  
Beta-mercaptoethanol 3.5 mL (100 mM) 
 
Dissolve Tris and SDS in deionized H2O and adjust the PH to 6.7. Add the 
mercaptoethanol and adjust the final volume to 500 mL. 
 
 Aβ-SDS-PAGE 
 
Equipment: 
 Mini-PROTEAN Tetra Handcast Systems (Biorad) 
 TE70XP Semi-Dry Transfer Unit (Hoefer) 
 Electrophoresis power supply EPS 1000 (Amersham Pharmacia Biotec) 
 
Reagents and solutions 
 
 Separating Gel Buffer 1.6M Tris/0,4M H2SO4 pH 8,1 
 
Tris-Base 19,38g 
0.5M H2SO4 80mL 
H2Odd Until 100mL 
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 Stacking Gel Buffer 0.8M Bistris/0,2M H2SO4 pH 6,7 
 
Bistris 8.37g 
0.5M H2SO4 20mL 
H2Odd Until 50mL 
 
 Comb Gel Buffer 0,72M Bistris/0,32M Bicine pH 7.7  
 
Bistris 30.04g 
Bicine 10,36g 
H2Odd 200mL 
 
 Rinsing Buffer 0,36M Bistris/0,16M Bicine/0,1% SDS pH 7,7 
 
Comb gel buffer 25mL 
1% SDS 5mL 
H2Odd Until 50mL 
 
 Anode Buffer 200mM Tris/50mM H2SO4 pH8.1 
 
Tris 24.23g 
0.5M H2SO4 100mL 
H2Odd Until 1000mL 
 
 Cathode Buffer 200mM Bicine/100 mM NaOH/0,25% SDS pH8,2 
 
Bicine 32.63g 
1M NaOH 100mL 
10% SDS 25mL 
H2Odd Until 1000mL 
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 Blot Buffer A Stock Solution 2,1M Tris ph 10,4 
 
Tris-Base 127.3g 
H2Odd 500mL 
 
 Blot Buffer B+C Stock Solution 250mM Tris pH 10,4 
 
Tris-Base 30.28g 
H2Odd 1000mL 
 
 0,5M Boric Acid 
 
Boric Acid 30.9g 
H2Odd 1000mL 
 
 Blot Buffer A 210mM Tis/30%v/v Methanol pH10,4 
 
Blot Buffer A Stock Solution 100mL 
Methanol 300mL 
H2Odd Until 1000mL 
 
 Blot Buffer B 25mM Tris/30%v/v Methanol pH10,4 
 
Blot Buffer B Stock Solution 100mL 
Methanol 300mL 
H2Odd Until 1000mL 
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 Blot Buffer C 25mM Tris/0.025% SDS pH 9. 
 
Blot Buffer C Stock Solution 200mL 
H2O 1600mL 
0.5M Boric Acid 20mL 
10% SDS 5mL 
H2Odd Until 1000mL 
 
